未经证实:胰腺神经内分泌肿瘤(pNETs)和实性假乳头状瘤(SPT)是两种最常见的胰腺肿瘤,治疗方法不同。然而,pNETs和SPT在临床表现和放射学特征上的广泛异质性经常混淆临床实践中的术前歧视,迄今为止,这两种肿瘤的临床和分子分化仍然难以捉摸。我们认为,对pNETs和SPT的多模态特征进行大规模而全面的研究对于精确的临床管理是必要的。
UASSIGNED:我们收集并分析了无功能pNET和SPT患者的临床病理信息和多模态特征,从2006年到2021年,共有631例。成像特征的单变量分析,包括对比增强计算机断层扫描(CT),磁共振成像,内镜超声(EUS)和核医学成像,并进行了临床特征,结合CT特征和临床信息建立列线图模型。
UNASSIGNED:我们招募了354名非功能性pNET患者和277名SPT患者。关于人口统计信息,pNET患者的女性比例较低(55.4%vs.72.9%),较小的肿瘤大小(2.8与4.8cm),和年龄较大(53.4vs.35.3年)。在CT成像和EUS中,pNETs倾向于表现为具有强烈增强强度的实体和均质病变。多灶性病变,导管扩张,淋巴结(LN)肿大更可能在pNET中观察到,而钙化在SPT病变中更为常见。在正电子发射断层扫描(PET)/CT上,pNETs对生长抑素受体闪烁显像(SRS)表现出明显的敏感性,99mTc-HYNIC-TOC和68Ga-DOTATATEPET/CT的阳性率分别为81.4%和95%,分别,而SPT在SRS上均为阴性。多变量分析确定肿瘤大小,年龄,增强强度,钙化,和LN扩大作为统计上显著的变量。
未经证实:与SPT患者相比,pNET患者表现出年龄较大和肿瘤尺寸较小。强强度的CT表现,LN放大,无钙化可能表明pNET的可能性较高。同时,免疫组织化学谱的相似性表明这两种肿瘤可能来自同一来源.
UNASSIGNED: Pancreatic neuroendocrine tumors (pNETs) and solid pseudopapillary tumors (SPTs) are two of the most common pancreatic neoplasms with different treatment procedures. However, the broad heterogeneity of pNETs and SPTs in clinical manifestations and radiological features often confuse the presurgical discrimination in clinical practice, and the clinical and molecular differentiation of the two tumors remains elusive to date. We presume that a large and comprehensive
study into the multimodality features of pNETs and SPTs is necessary for precise clinical management.
UNASSIGNED: We collected and analyzed the clinicopathological information and multimodality features of nonfunctional pNET and SPT patients, for a total of 631 cases from 2006 to 2021. Univariate analysis of imaging features, including contrast-enhanced computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound (EUS) and nuclear medicine imaging, and clinical characteristics was performed, and CT features and clinical information were integrated to establish a nomogram model.
UNASSIGNED: We recruited 354 nonfunctional pNET and 277 SPT patients in our cohort. Regarding demographic information, pNET patients had a lower female percentage (55.4% vs. 72.9%), smaller tumor size (2.8 vs. 4.8 cm), and older age (53.4 vs. 35.3 years). In CT imaging and EUS, pNETs tended to appear as solid and homogenous lesions with strong enhancement intensity. Multifocal lesions, duct dilation, and lymph node (LN) enlargement were more likely to be observed in pNETs, while calcification was more common in SPT lesions. On positron emission tomography (PET)/CT, pNETs exhibited significant sensitivity to somatostatin receptor scintigraphy (SRS), with positive rates of 81.4% and 95% on 99mTc-HYNIC-TOC and 68Ga-DOTATATE PET/CT, respectively, while SPTs were all negative on SRS. Multivariate analysis identifies tumor size, age, enhancement intensity, calcification, and LN enlargement as statistically significant variables.
UNASSIGNED: Compared to SPT patients, pNET patients exhibit an older age and smaller tumor size. CT manifestations of strong intensity, LN enlargement, and no calcification could indicate a higher possibility of pNET. Meanwhile, the similarity in the immunohistochemical profile indicates that the two tumors could potentially develop from the same origin.